we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
![Halozyme Therapeutics logo](/files/LOGO/1159036-HALO.png)
Company profile
Ticker
HALO
Exchange
Website
CEO
Helen Torley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GLOBAL YACHT SERVICES INC, HALOZYME THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Halozyme, Inc. • Antares Pharma, Inc. • Antares Pharma IPL AG • Antares Pharma AG ...
IRS number
880488686
HALO stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Halozyme Reports First Quarter 2024 Financial and Operating Results
7 May 24
8-K
Submission of Matters to a Vote of Security Holders
26 Apr 24
ARS
2023 FY
Annual report to shareholders
15 Mar 24
DEFA14A
Additional proxy soliciting materials
15 Mar 24
DEF 14A
Definitive proxy
15 Mar 24
PRE 14A
Preliminary proxy
4 Mar 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
Halozyme Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
20 Feb 24
8-K
Results of Operations and Financial Condition
17 Jan 24
Transcripts
HALO
Earnings call transcript
2024 Q1
7 May 24
HALO
Earnings call transcript
2023 Q4
20 Feb 24
HALO
Earnings call transcript
2023 Q3
6 Nov 23
HALO
Earnings call transcript
2023 Q2
8 Aug 23
HALO
Earnings call transcript
2023 Q2
8 Aug 23
HALO
Earnings call transcript
2023 Q1
9 May 23
HALO
Earnings call transcript
2022 Q4
21 Feb 23
HALO
Earnings call transcript
2022 Q3
9 Nov 22
HALO
Earnings call transcript
2022 Q2
9 Aug 22
HALO
Earnings call transcript
2022 Q1
11 May 22
Latest ownership filings
4
Michael J. LaBarre
24 Jul 24
144
Notice of proposed sale of securities
24 Jul 24
4
Nicole LaBrosse
23 Jul 24
144
Notice of proposed sale of securities
23 Jul 24
144
Notice of proposed sale of securities
22 Jul 24
144
Notice of proposed sale of securities
28 Jun 24
4
Nicole LaBrosse
28 Jun 24
144
Notice of proposed sale of securities
27 Jun 24
144
Notice of proposed sale of securities
26 Jun 24
4
Michael J. LaBarre
20 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2024
97.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 397 |
Opened positions | 132 |
Closed positions | 48 |
Increased positions | 120 |
Reduced positions | 101 |
13F shares | Current |
---|---|
Total value | 4.47 tn |
Total shares | 123.83 mm |
Total puts | 139.80 k |
Total calls | 216.20 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 18.24 mm | $742.07 bn |
Vanguard | 13.05 mm | $530.84 bn |
STT State Street | 6.49 mm | $263.90 bn |
Snyder Capital Management L P | 4.12 mm | $167.49 bn |
BBBOF BB Biotech | 3.97 mm | $169.56 mm |
Artisan Partners Limited Partnership | 3.79 mm | $154.23 bn |
Alliancebernstein | 3.67 mm | $149.15 bn |
JPM JPMorgan Chase & Co. | 3.24 mm | $131.82 bn |
Geode Capital Management | 3.03 mm | $123.17 bn |
MCQEF Macquarie | 2.99 mm | $121.68 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jul 24 | LaBarre Michael J. | Common Stock | Sell | Dispose S | No | Yes | 55.115 | 10,000 | 551.15 k | 168,176 |
24 Jul 24 | LaBarre Michael J. | Common Stock | Option exercise | Acquire M | No | Yes | 16.65 | 8,285 | 137.95 k | 178,176 |
24 Jul 24 | LaBarre Michael J. | Common Stock | Option exercise | Acquire M | No | Yes | 8.11 | 1,715 | 13.91 k | 169,891 |
24 Jul 24 | LaBarre Michael J. | Option to Purchase Common Stock Common Stock | Option exercise | Dispose M | No | Yes | 16.65 | 8,285 | 137.95 k | 51,861 |
24 Jul 24 | LaBarre Michael J. | Option to Purchase Common Stock Common Stock | Option exercise | Dispose M | No | Yes | 8.11 | 1,715 | 13.91 k | 0 |
23 Jul 24 | LaBarre Michael J. | Common Stock | Sell | Dispose S | No | Yes | 55.265 | 5,291 | 292.41 k | 168,176 |
23 Jul 24 | LaBarre Michael J. | Common Stock | Sell | Dispose S | No | Yes | 54.463 | 4,709 | 256.47 k | 173,467 |
23 Jul 24 | LaBarre Michael J. | Common Stock | Option exercise | Acquire M | No | Yes | 8.11 | 10,000 | 81.10 k | 178,176 |
23 Jul 24 | LaBarre Michael J. | Option to Purchase Common Stock Common Stock | Option exercise | Dispose M | No | Yes | 8.11 | 10,000 | 81.10 k | 1,715 |
22 Jul 24 | Nicole LaBrosse | Common Stock | Sell | Dispose S | No | Yes | 54.253 | 992 | 53.82 k | 15,480 |
News
Goldman Sachs Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $49
22 Jul 24
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
16 Jul 24
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target
16 Jul 24
Why Is Kodiak Sciences Down 26.2% Since Last Earnings Report?
14 Jun 24
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
9 Jun 24
Press releases
Halozyme to Report Second Quarter 2024 Financial and Operating Results
23 Jul 24
Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval
17 Jul 24
Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024
11 Jul 24
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
9 Jul 24
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
17 Jun 24